Literature DB >> 11606002

Genetic liability, illicit drug use, life stress and psychotic symptoms: preliminary findings from the Edinburgh study of people at high risk for schizophrenia.

P Miller1, S M Lawrie, A Hodges, R Clafferty, R Cosway, E C Johnstone.   

Abstract

BACKGROUND: Studies of groups at high risk of developing schizophrenia have tended to be based on subjects recruited to the study in their infancy. This paper reports on subjects at genetic high risk for schizophrenia assessed as young adults, close to the age when most onsets of schizophrenia occur.
METHODS: One hundred and fifty-five young people at elevated risk for the development of schizophrenia and 36 controls not at increased risk were assessed on entry to the Edinburgh High Risk Study. The measures included current psychotic symptoms, past and present cannabis and other drug use, lifetime life events and two aspects of genetic liability to schizophrenia.
RESULTS: Cannabis and other illicit drug use were significantly associated with symptoms in both groups. The same held true for the more upsetting life events experienced, but not for less upsetting ones. Within the high-risk group, there was no relationship between symptoms and a measure of genetic loading, but there was some slight evidence of a higher risk of symptoms when affected relatives were on the father's rather than the mother's side of the family.
CONCLUSIONS: Cannabis use, use of other illicit substances and upsetting life events may all lead to psychotic symptoms in vulnerable young people.

Entities:  

Mesh:

Year:  2001        PMID: 11606002     DOI: 10.1007/s001270170038

Source DB:  PubMed          Journal:  Soc Psychiatry Psychiatr Epidemiol        ISSN: 0933-7954            Impact factor:   4.328


  28 in total

Review 1.  Cannabis and psychosis.

Authors:  Louisa Degenhardt; Wayne Hall
Journal:  Curr Psychiatry Rep       Date:  2002-06       Impact factor: 5.285

Review 2.  Cannabis and psychosis.

Authors:  David M Fergusson; Richie Poulton; Paul F Smith; Joseph M Boden
Journal:  BMJ       Date:  2006-01-21

3.  The Edinburgh High Risk Study: current status and future prospects.

Authors:  Eve C Johnstone; Kirsten D Russell; Lesley K Harrison; Stephen M Lawrie
Journal:  World Psychiatry       Date:  2003-02       Impact factor: 49.548

Review 4.  Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction.

Authors:  Ruud van Winkel; Nicholas C Stefanis; Inez Myin-Germeys
Journal:  Schizophr Bull       Date:  2008-08-20       Impact factor: 9.306

5.  Abnormal stress responsivity in a rodent developmental disruption model of schizophrenia.

Authors:  Eric C Zimmerman; Mark Bellaire; Samuel G Ewing; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2013-05-08       Impact factor: 7.853

6.  Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis.

Authors:  Cheryl M Corcoran; David Kimhy; Arielle Stanford; Shamir Khan; Julie Walsh; Judy Thompson; Scott Schobel; Jill Harkavy-Friedman; Ray Goetz; Tiziano Colibazzi; Victoria Cressman; Dolores Malaspina
Journal:  Schizophr Res       Date:  2008-09-21       Impact factor: 4.939

Review 7.  Prefrontal cortical network connections: key site of vulnerability in stress and schizophrenia.

Authors:  Amy F T Arnsten
Journal:  Int J Dev Neurosci       Date:  2011-02-21       Impact factor: 2.457

8.  Adolescent stress contributes to aberrant dopamine signaling in a heritable rodent model of susceptibility.

Authors:  Stephanie M Perez; Daniel J Lodge
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2019-07-10       Impact factor: 5.067

9.  Cannabis and Psychosis: What Can Daily Diaries Tell Us About Who is Vulnerable?

Authors:  David Kimhy; Kelly Durbin; Cheryl M Corcoran
Journal:  Prim psychiatry       Date:  2009

Review 10.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.